App-Quantinova.ai

Transfusion 2024 – defining a 5‐year national strategy for clinical and laboratory transfusion practice

S. Allard - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Patient Identification errors in transfusion continue to be a problem

S. Carter-Graham - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Re‐evaluation of therapeutic plasma exchange and compliance with policy at a Tertiary Referral Hospital

B. Gration - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Human serum albumin

Red blood cell antibodies and adverse transfusion events in multi‐transfused patients with sickle cell disease in Ghana

L. A. Boateng - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sickle cell anemia

N/A

Transfusion in iron deficiency anaemia: retrospective audit of the frequency and nature of transfusion in the context of iron deficiency in Scottish hospital

S. Beverstock - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anemia

N/A

Avoidable Red cell transfusion due to Inadequate Investigation of Anaemia (ARIIA): A national study to determine if the patients that were transfused in an acute care setting were appropriately investigated for the causes of the anaemia

A. Rampotas - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Cyanocobalamin

Impact of Fetal RHD screening upon a UK hospital's practice for Routine Antenatal Anti‐D Prophylaxis (RAADP)

A. M. Y. Li - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Audit of red cell genotyping in sickle cell disease patients in two London trusts

Y. M. T. Hui - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Allopurinol

Re‐evaluating the shelf‐life of whole blood for use in trauma: impact of storage on platelet function

S. Huish - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Trauma

N/A

Prophylactic donor lymphocyte infusion reduces the risk of relapse and increases survival in patients with mixed T cell chimerism after reduced intensity allogeneic stem cell transplantation

R. Buka - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Graft-versus-host disease

N/A

Defibrotide treatment for veno‐occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: outcomes by severity and multi‐organ failure status in an observational registry study

S. Lawson - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic veno-occlusive disease with immunodeficiency

Defibrotide

Outcomes of Allografts for Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients Aged over 60 years and over 65 years are not inferior to those of younger patients: a single centre study

L. Burgess - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Allopurinol

The use of Autologous Haematopoietic Stem Cell Transplants in patients with Relapsing Remitting Multiple Sclerosis (RRMS): A Meta‐Analysis

O. Greaves - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Alemtuzumab

Alemtuzumab containing renal transplant protocols are associated with late onset EBV+ PTLD, with poorer overall survival

M. Fareen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Post-transplant lymphoproliferative disorder

Alemtuzumab

First report of post‐transplant autoimmune hyperlipidaemia and treatment with rituximab

W. Y. C. Sin - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Autoimmune hemolytic anemia

Atorvastatin

Reduced Intensity Conditioning with Thiotepa‐Fludarabine‐Busulphan (TBF) and Post‐Transplant Cyclophosphamide (PTC) Results in Rapid Complete Donor T‐cell Chimerism in Haploidentical Recipients with Acute Myeloid Leukaemia

R. Banerjee - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cyclophosphamide

Morbidity of very long term (>30 year) survivors of allogeneic haemopoietic cell transplantation 1979‐1989: a single centre experience

N. Salooja - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Outcomes following treatment discontinuation in chronic myeloid leukaemia (CML): real‐world experience from three regional UK centres

F. Wandroo - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Interferon alpha

Could CD45 have a role in the development of myeloid malignancies?

M. Al Barashdi - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Alendronate sodium

The impact of PCR thermocycling conditions, DNA template concentration and intraoperator variation on determining allelic ratio in the detection of FLT3‐ITD mutations in AML

A. Robinson - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Midostaurin

Filters

45280 Abstracts